Tag:
XmAb587
Latest Headlines
Latest Headlines
Amgen licenses Xencor's early-stage autoimmune drug
Amgen has secured the option to co-develop Xencor's preclinical autoimmune drug XmAb5871, which targets CD19 and CD32b. Xencor gains undisclosed upfront and milestone payments for early development
